DelveInsight Highlights Major Advances, Transformative Therapies, and 150+ Leading Players Wheeling the Acute Lymphocytic Leukemia Clinical Trial Pipeline Landscape

September 05 02:00 2023
DelveInsight Highlights Major Advances, Transformative Therapies, and 150+ Leading Players Wheeling the Acute Lymphocytic Leukemia Clinical Trial Pipeline Landscape

The Acute Lymphocytic Leukemia Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Acute Lymphocytic Leukemia treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Acute Lymphocytic Leukemia pipeline landscape and fostering the potential growth of Acute Lymphocytic Leukemia therapeutic advancements.

 

Key Takeaways from the Acute Lymphocytic Leukemia Pipeline Report

  • DelveInsight’s Acute Lymphocytic Leukemia pipeline report depicts a robust space with 150+ active players working to develop 160+ pipeline therapies for Acute Lymphocytic Leukemia treatment.
  • The leading companies working in the Acute Lymphocytic Leukemia market include PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
  • Promising Acute Lymphocytic Leukemia Pipeline Therapies in the various stages of development include Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), Imatinib Mesylate, LCAR-AIO Cells, Decitabine, SAR443579, and others.
  • On January 2023, Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd announced a study of Phase 1 clinical trials for CD19 CAR-T cells. This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
  • On February 2023, Shanghai Ming Ju Biotechnology Co., Ltd. announced a study of Phase 1 clinical trials for CD19-targeted Chimeric Antigen Receptor (CAR) T Cells. This is a phase I, open-label, single-arm study conducted in China to evaluate the safety, tolerability, PK, and determine the recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD) (if applicable) of JWCAR029 in pediatric and young adult subjects with r/r B-ALL.
  • On March 2023, Sichuan Baili Pharmaceutical Co., Ltd. announced a study of Phase 1 clinical trials for GNC-038. An open, multicenter, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacokinetics, and antitumor activity of GNC-038 quad-specific antibody injection in relapsed or refractory non-Hodgkin’s lymphoma, relapsed or refractory acute lymphoblastic leukemia, and refractory or metastatic solid tumors
  • On August 2023, Sanofi announced a study of Phase 1 & 2 clinical trials for SAR443579. This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.

 

Request a sample and discover the recent advances in Acute Lymphocytic Leukemia Treatment Drugs @ Acute Lymphocytic Leukemia Infection Pipeline Report

 

The Acute Lymphocytic Leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Glioblastoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Lymphocytic Leukemia clinical trial landscape.

 

Acute Lymphocytic Leukemia Overview

Acute Lymphocytic Leukemia (ALL) (ALL) is also called acute lymphoblastic leukemia. “Acute” means that the leukemia can progress quickly, and if not treated, would probably be fatal within a few months. “”Lymphocytic”” means it develops from early (immature) forms of lymphocytes, a type of white blood cell.

 

Find out more about Acute Lymphocytic Leukemia Treatment Drugs @ Drugs for Acute Lymphocytic Leukemia Treatment

 

Acute Lymphocytic Leukemia Emerging Drugs Profile

  • CPX-351: Jazz Pharmaceuticals
  • JZP-458: Jazz Pharmaceuticals
  • UCART22: Cellectis
  • JZP-341: Jazz Pharmaceuticals

 

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 150+ key companies which are developing the therapies for Acute Lymphocytic Leukemia (ALL). The Acute Lymphocytic Leukemia companies which have their Acute Lymphocytic Leukemia (ALL) drug candidates in the most advanced stage, i.e. phase II/III include Jazz Pharmaceuticals and others.

 

Learn more about the emerging Acute Lymphocytic Leukemia Pipeline Therapies @ Acute Lymphocytic Leukemia Clinical Trials Assessment

 

Scope of the Acute Lymphocytic Leukemia Pipeline Report

  • Coverage- Global
  • Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Acute Lymphocytic Leukemia Companies- PersonGen BioTherapeutics, Novartis Pharmaceuticals, Jazz Pharmaceuticals, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Pinze Lifetechnology Co. Ltd., Celgene, and others.
  • Acute Lymphocytic Leukemia Pipeline Therapies- Inotuzumab Ozogamicin, CD19 CAR-T cells, clofarabine, FLAG (fludarabine, cytarabine and G-CSF), HIDAC (high dose cytarabine), cytarabine and mitoxantrone, Blinatumomab, Marqibo® (vincristine sulfate liposomes injection), Imatinib Mesylate, LCAR-AIO Cells, Decitabine, SAR443579, and others.

 

Dive deep into rich insights for new drugs for Acute Lymphocytic Leukemia treatment, Visit @ Acute Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Acute Lymphocytic Leukemia (ALL): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Acute Lymphocytic Leukemia (ALL) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Acute Lymphocytic Leukemia (ALL) Collaboration Deals
  9. Late Stage Products (Phase III and Phase II/III)
  10. JZP-458: Jazz Pharmaceuticals
  11. Mid Stage Products (Phase II)
  12. CPX-351: Jazz Pharmaceuticals
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. UCART22: Cellectis
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. JZP-341: Jazz Pharmaceuticals
  19. Inactive Products
  20. Acute Lymphocytic Leukemia (ALL) Key Companies
  21. Acute Lymphocytic Leukemia (ALL) Key Products
  22. Acute Lymphocytic Leukemia (ALL)- Unmet Needs
  23. Acute Lymphocytic Leukemia (ALL)- Market Drivers and Barriers
  24. Acute Lymphocytic Leukemia (ALL)- Future Perspectives and Conclusion
  25. Acute Lymphocytic Leukemia (ALL) Analyst Views
  26. Acute Lymphocytic Leukemia (ALL) Key Companies
  27. Appendix

 

For further information on the Acute Lymphocytic Leukemia pipeline therapeutics, reach out to Acute Lymphocytic Leukemia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking